Public release date: 16-Oct-2012 [ | E-mail | Share ] <\/p>\n
Contact: Anne DeLotto Baier abaier@health.usf.edu<\/a> 813-974-3303 University of South Florida (USF Health)<\/p>\n Tampa, FL (Oct. 16, 2012) -- A landmark paper identifying genetic signatures that predict which patients will respond to a life-saving drug for treating congestive heart failure has been published by a research team co-led by Stephen B. Liggett, MD, of the University of South Florida. <\/p>\n The study, drawing upon a randomized placebo-controlled trial for the beta blocker bucindolol, apprears this month in the online international journal PLoS ONE. In addition to Dr. Liggett, whose laboratory discovered and characterized the two genetic variations, Christopher O'Connor, MD, of Duke University Medical Center, and Michael Bristow, MD, PhD, of ARCA biopharma and the University of Colorado Anschutz Medical Campus, were leading members of the research team. <\/p>\n The analysis led to a \"genetic scorecard\" for patients with congestive heart failure, a serious condition in which the heart can't pump enough blood to meet the body's needs, said Dr. Liggett, the study's co-principal investigator and the new vice dean for research and vice dean for personalized medicine and genomics at the USF Morsani College of Medicine. <\/p>\n \"We have been studying the molecular basis of heart failure in the laboratory with a goal of finding genetic variations in a patient's DNA that alter how drugs work,\" Dr. Liggett said. \"We took this knowledge from the lab to patients and found that we can indeed, using a two-gene test, identify individuals with heart failure who will not respond to bucindolol and those who have an especially favorable treatment response. We also identified those who will have an intermediate level of response.\" <\/p>\n The research has implications for clinical practice, because the genetic test could theoretically be used to target the beta blocker to patients the drug is likely to help. Equally important, its use could be avoided in patients with no likelihood of benefit, who could then be spared potential drug side effects. Prospective studies are needed to confirm that bucindolol would be a better treatment than other classes of beta blockers for a subset of patients with health failure. <\/p>\n Dr. Liggett collaborated with medical centers across the United States, including the NASDAq-listed biotech company ARCA biopharma, which he co-founded in Denver, CO. This genetic sub-study involved 1,040 patients who participated in the Beta-Blocker Evaluation of Survival Trial (BEST). The researchers analyzed mortality, hospital admissions for heart failure exacerbations and other clinical outcome indicators of drug performance. <\/p>\n \"The results showed that the choice of the best drug for a given patient, made the first time without a trial-and-error period, can be accomplished using this two-gene test,\" Dr. Liggett said. <\/p>\n The genetic test discovered by the Liggett team requires less than 1\/100th of a teaspoon of blood drawn from a patient, from which DNA is isolated. DNA is highly stable when frozen, so a single blood draw will suffice for many decades, Dr. Liggett said. And since a patient's DNA does not change over their lifetime, as new discoveries are made and other tests need to be run, it would not be necessary to give another blood sample, he added. <\/p>\n<\/p>\n Read the original here: Public release date: 16-Oct-2012 [ | E-mail | Share ] Contact: Anne DeLotto Baier abaier@health.usf.edu<\/a> 813-974-3303 University of South Florida (USF Health) Tampa, FL (Oct. 16, 2012) -- A landmark paper identifying genetic signatures that predict which patients will respond to a life-saving drug for treating congestive heart failure has been published by a research team co-led by Stephen B. Continue reading
\n2-gene test predicts which patients with heart failure respond best to beta-blocker drug<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"